Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.32080 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Claudia Pasqualini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Immunotherapy, Neuroblastoma. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Hubert Gouin Enfance et Cancer, Fondation du LEEM, Imagine for Margo.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with high‐risk neuroblastoma (HR‐NBL) who experience disease progression (PD) during first‐line treatment prior to high‐dose chemotherapy (HDC) represent a rare and understudied subgroup, for whom treatment strategies are poorly defined and prognosis appears to be extremely poor.
Aims
We report real‐world data on the off‐label use of chemo‐immunotherapy for HR‐NBL patients with PD before HDC. The primary endpoint of our analysis is the best response during the chemo‐immunotherapy treatment.
Methods
The SACHA‐France registry prospectively documents safety and efficacy data on compassionate/off‐label treatments for patients of ≤25 years old (NCT04477681).
Results
Between January 2020 and September 2024, 13 patients with HR‐NBL received chemo‐immunotherapy due to PD before HDC, and were included in SACHA‐France. They had a median age of 3.4 years (1.3–8.0). Six patients had NMYC‐amplified disease. Five PD occurred during/end‐of‐induction chemotherapy, and eight during temozolomide‐based chemotherapy after initial insufficient metastatic response or toxicity. All but one had metastatic progression. The chemo‐immunotherapy consisted of topotecan–cyclophosphamide ( n = 9) or temozolomide–irinotecan ( n = 4), combined with dinutuximab beta (dB) for a maximum of six cycles. Objective responses (ORs) were seen in five of 13 patients (38%)—four partial responses (PR) and one complete response (CR). Three out of the five patients with PD during/end of induction had PR, including two with NMYC‐amplified tumors. Overall, six patients underwent tandem HDC, with two remaining progression‐free after 1.7 and 2.1 years, and one remaining disease‐free at 3.4 years.
Conclusion
Chemo‐immunotherapy can benefit HR‐NBL patients with PD before HDC, including those with progression during/at the end of the induction chemotherapy and NMYC amplification. These findings support its early inclusion in HR‐NBL trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
- Department of Pediatric Oncology, University Hospital, Angers, France.
- SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer); RTOP (Recherche Translationelle en Oncologie Pediatrique), U830 INSERM, Institut Curie, PSL Research University, Paris, France.
- Department of Pediatric Oncology, Toulouse University Hospital, Toulouse, France.
- Pediatric Onco-Hematology Unit, University Hospital of Strasbourg, Strasbourg, France.
- Department of Pediatric Hematology and Oncology, Hôpital Armand Trousseau, Paris, France.
ORCID-Profile: Claudia Pasqualini, Gudrun Schleiermacher, Lee Aymar Ndounga-Diakou, Anne Sophie Defachelles, Pablo Berlanga
Förderung
- Association Hubert Gouin Enfance et Cancer
- Fondation du LEEM
- Imagine for Margo
- Fight Kids Cancer
Zitieren
APA
Pasqualini, C., Proust, S., Schleiermacher, G., Gambart, M., Jannier, S., Petit, A., Dupraz, C., Thebaud, E., Reguerre, Y., Ndounga-Diakou, L. A., Laghouat, S., Defachelles, A. S., & Berlanga, P. (2025). Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32080
Vancouver
Pasqualini C, Proust S, Schleiermacher G, Gambart M, Jannier S, Petit A, et al. Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32080
BibTeX
@article{Pasqualini2025,
author = {Pasqualini, Claudia and Proust, Stéphanie and Schleiermacher, Gudrun and Gambart, Marion and Jannier, Sarah and Petit, Arnaud and Dupraz, Chrystelle and Thebaud, Estelle and Reguerre, Yves and Ndounga-Diakou, Lee Aymar and Laghouat, Salim and Defachelles, Anne Sophie and Berlanga, Pablo},
title = {Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.32080}
}
EUVIMED